Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 2/20 | 0.48 |
| ▸ | MMP2 | P08253 | 2/20 | 0.48 |
| ▸ | MMP3 | P08254 | 2/20 | 0.48 |
| ▸ | MMP7 | P09237 | 2/20 | 0.48 |
| ▸ | MMP13 | P45452 | 2/20 | 0.48 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.47 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.45 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.45 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.45 |
| ▸ | HPN | P05981 | 4/20 | 0.45 |
| ▸ | PLAU | P00749 | 3/20 | 0.45 |
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | HTR1E | P28566 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12435220 | 0.89 | HPN (0.55) | MMP1MMP2MMP3MMP7MMP13 | |
| SCHEMBL12467275 | 0.83 | ADAM17 (0.47) | MMP1MMP2MMP3MMP7MMP13 | |
| SCHEMBL19187443 | 0.81 | HPN (0.54) | MMP1MMP2MMP3MMP7MMP13 | |
| SCHEMBL6979815 | 0.79 | SLC1A3 (0.60) | MMP13ADAM17SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL12401646 | 0.76 | MMP2 (0.36) | MMP1MMP2MMP3MMP7MMP13 | |
| SCHEMBL12435216 | 0.74 | MMP2 (0.35) | MMP1MMP2MMP3MMP7MMP13 | |
| SCHEMBL12435248 | 0.74 | ALDH1A1 (0.49) | MMP2MMP3SLC1A3PYGL | |
| SCHEMBL1770556 | 0.73 | ADAM17 (0.60) | MMP1MMP2MMP3MMP7MMP13 | |
| SCHEMBL1770561 | 0.73 | ADAM17 (0.60) | MMP1MMP2MMP3MMP7MMP13 | |
| SCHEMBL1770350 | 0.72 | MMP1 (0.67) | MMP1MMP2MMP3MMP13ADAM17 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2528922-B1 | POLYHETEROCYCLIC COMPOUNDS AS HCV INHIBITORS | AB PHARMA LTD (CN) | 2017-08-02 | — | — | EP | disclosed |
| WO-2011091757-A1 | POLYHETEROCYCLIC COMPOUNDS HIGHLY POTENT AS HCV INHIBITORS | AB Pharma Ltd. (CN) | 2011-08-04 | — | — | WO | disclosed |
| US-20110183895-A1 | POLYHETEROCYCLIC COMPOUNDS HIGHLY POTENT AS HCV INHIBITORS | AB Pharma Ltd. (CN) | 2011-07-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110183895-A1 | POLYHETEROCYCLIC COMPOUNDS HIGHLY POTENT AS HCV INHIBITORS | HAVCR2, ZC3HAV1, EIF2AK2 | MMP1 2251/4885MMP2 724/4885MMP3 2988/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.